Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy

FDA recall notice · announced September 10, 2025 · Boothwyn Pharmacy

Class II FDA/FSIS Class II: use may cause temporary or medically reversible adverse health consequences.

The product

Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy

Reason for recall

Subpotent Drug

Notes

Distribution: U.S. Nationwide
Lot/code information: 03202025@9 BUD 07/18/2025
Quantity: 186 vials
Status: Ongoing
Products in this recall event:
- Fluorescein 2% Ophth, 3 ML, Boothwyn Pharmacy, 800-476-7496 (D-0607-2025)
- Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy (D-0606-2025)
- Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy (D-0609-2025)
- Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy (D-0608-2025)

Source: U.S. Food and Drug Administration public recall data. This page reports official records and is not legal, medical, or repair advice.